Company intelligence / Profile preview

Halt Medical

Livermore, California, United States

Ownership: Private
Development stage: Other

Overview

Halt Medical developed the Acessa System (also called Halt Global Fibroid Ablation System), which received FDA approval in November for treating uterine fibroids. The device uses radiofrequency ablation technology to treat fibroids while preserving normal uterine function. The company completed a 137-patient IDE clinical trial at 11 sites in 3 countries demonstrating clinical safety and efficacy.

Therapeutic areas: Women's Health
Modalities: Device
Industry: Therapeutic Medical Devices

Beyond the preview

Go deeper on Halt Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Halt Medical.

Explore the full profile